Eli Lilly and Company (NYSE:LLY) Shares Purchased by Hancock Whitney Corp

Hancock Whitney Corp boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 16.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,484 shares of the company’s stock after purchasing an additional 5,982 shares during the period. Eli Lilly and Company comprises approximately 1.3% of Hancock Whitney Corp’s investment portfolio, making the stock its 14th biggest holding. Hancock Whitney Corp’s holdings in Eli Lilly and Company were worth $37,559,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in LLY. Twelve Points Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 1.4% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company’s stock valued at $734,000 after purchasing an additional 11 shares in the last quarter. Verum Partners LLC lifted its holdings in Eli Lilly and Company by 1.5% during the 2nd quarter. Verum Partners LLC now owns 731 shares of the company’s stock worth $662,000 after buying an additional 11 shares during the last quarter. Acorn Creek Capital LLC boosted its position in shares of Eli Lilly and Company by 1.3% during the 2nd quarter. Acorn Creek Capital LLC now owns 927 shares of the company’s stock worth $840,000 after acquiring an additional 12 shares in the last quarter. Thompson Davis & CO. Inc. lifted its stake in Eli Lilly and Company by 0.7% during the second quarter. Thompson Davis & CO. Inc. now owns 1,687 shares of the company’s stock worth $1,527,000 after purchasing an additional 12 shares during the last quarter. Finally, O Brien Greene & Co. Inc boosted its holdings in Eli Lilly and Company by 1.3% in the second quarter. O Brien Greene & Co. Inc now owns 955 shares of the company’s stock valued at $865,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.7 %

NYSE:LLY opened at $921.72 on Friday. The stock has a fifty day simple moving average of $895.06 and a 200-day simple moving average of $837.89. The company has a market capitalization of $876.01 billion, a PE ratio of 135.75, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Analyst Ratings Changes

Several brokerages have issued reports on LLY. Guggenheim raised their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Barclays boosted their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the sale, the insider now owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 442,229 shares of company stock valued at $410,002,456 over the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.